Sandoz distinguishes itself through its ability to offer generics that are differentiated. Its broad portfolio ranges from advanced application forms -- such as oral solids -- through complex technologies -- such as inhalants and injectables -- and includes transdermal patches.
Sandoz holds one of the most significant product portfolios in Canada with 280 molecules, including 20 of the 25 most important molecules on the market.
With roots dating back to more than 120 years and as part of the Novartis Group, Sandoz is a trusted leader with a reputation for exceptional quality.
To learn more about our products, click here.